TO STUDY THE EFFECT OF A DRUG (SAROGLITAZAR) USED TO TREAT DYSLIPIDEMIA ON THE RISK MARKERS OF HEART DISEASE
Not Applicable
- Conditions
- Health Condition 1: E785- Hyperlipidemia, unspecified
- Registration Number
- CTRI/2022/09/046049
- Lead Sponsor
- Dayanand Medical college and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Dyslipidemia not controlled with statins for at least 3 months
Exclusion Criteria
1. Significant alcohol intake ( > 140 g/week in females and > 210 g/week in males)
2. Uncontrolled thyroid disease
3. Active cardio-pulmonary disease.
4. Current/past history of malignancy.
5. Chronic liver disease, viral hepatitis or chronic kidney disease (CKD).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method